Drug Discovery World

SEPTEMBER 9, 2024

Producing treatments for unmet medical needs: AI offers the tools to examine complex diseases comprehensively. This capability allows AI to identify potential treatment strategies that consider multiple factors simultaneously, leading to the discovery of drug candidates that might not have been previously considered.

Drugs 162

Drugs Bioinformatics Computational Chemistry International 162

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. The university aims to identify treatments for life-threatening anti-microbial diseases and metabolic disorders.

Drugs 189

Drugs Science Therapies Targeted Protein Degradation 189

Drug Discovery World

APRIL 25, 2023

Spin-out companies play a vital role in translating Cancer Research UK-funded research from the lab into life-saving treatments. Dawn Bio which is a drug discovery platform based on human embryo models for drug development for women’s reproductive health.

Science 130

Science Small Molecule Disease Government 130

The Pharma Data

DECEMBER 15, 2020

FDA Approves Klisyri (tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp. NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. BUFFALO, N.Y.,

FDA Approval 52

FDA Approval FDA Treatment Small Molecule 52

The Premier Consulting Blog

JULY 9, 2023

During the development of new small molecule drug products, developers must conduct impurity and degradant evaluation at several points in the program and to varying degrees. The TTC varies based on the clinical treatment duration and on whether multiple mutagenic impurities are present.

Small Molecule 52

Small Molecule DNA Drugs Clinical Development 52

Vial

DECEMBER 11, 2023

Despite advances in clinical research, there remain significant challenges as only 20% of HCV cases are diagnosed, and of these, only 15% receive treatment. The Food and Drug Administration (FDA) approved and recommended dozens of small-molecule drugs.

Clinical Research 52

Clinical Research Therapies Research Vaccine 52

The Pharma Data

OCTOBER 18, 2020

DUBLIN–( BUSINESS WIRE )– Inflection Biosciences Ltd , a company developing innovative therapeutics for the treatment of cancer, today announced the appointment of industry veteran Gregory I. Inflection Biosciences Ltd is developing small molecule therapeutics for the treatment of cancer.

Small Molecule 40

Small Molecule Clinical Development Clinical Trials Licensing 40

Drug Discovery World

NOVEMBER 17, 2022

However, the development of drugs takes decades which is too long for most biotech start- ups looking for fast-track drug development programs. Antibiotic drug discovery once largely consisted of scientists growing streptomyces or bacillus in the lab and bottling their secrets to treat human disease. .

Engineering 130

Engineering Molecular Biology Synthetic Chemistry DNA 130

Drug Target Review

NOVEMBER 22, 2023

Whilst TGF-β is an attractive target for cancer therapy because of its critical role in promoting tumor aggressiveness, immune escape and resistance to therapy, activation of alternative resistance pathways has hindered drug development attempts in the past. Are there any unique strategies or approaches being considered?

Licensing 52

Licensing Licensing Small Molecule Therapies 52

Drug Discovery World

AUGUST 5, 2022

Ian Hollingsworth, Associate Director of product development at Boyds, the global drug development consultancy, explains the benefits to the drug development lifecycle of building strong partnerships with external consultants, and when and how to get the best from them. Why sponsors use external consultants.

Drug Development 130

Drug Development Drugs Pharma Companies International 130

The Pharma Data

NOVEMBER 1, 2020

Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company is managed by a team with broad international, commercial and clinical-science experience.

Clinical Pharmacology 52

Clinical Pharmacology Small Molecule Clinical Research Science 52

NIH Director's Blog: Drug Development

MAY 21, 2020

One advantage of this class of therapeutics is that the timelines for their development, testing, and approval are typically shorter than those for drugs made of chemical compounds, called small molecules. So, what exactly led up to this latest scientific achievement?

Virus 52

Virus Vaccine Laboratories Small Molecule 52

Drug Discovery World

AUGUST 2, 2023

For instance, protein palmitoylation involves the covalent attachment of fatty acyl chains, typically a palmitate to internal cysteine residues of a protein via labile thioester linkages. Ezurpimtrostat (GNS561) was identified from a large library of small molecules as a lead compound for drug development.

Small Molecule 130

Small Molecule Immune Response Clinical Trials International 130

The Pharma Data

DECEMBER 14, 2020

The global GBM treatment market is projected to reach $3.3 The ability of a drug candidate to cross the blood brain barrier is of critical importance in treatment outcomes for CNS and brain cancers. Many drugs fail in clinical trials because of their low blood brain barrier permeability. .

DNA 52

DNA Clinical Trials Drugs Therapies 52

The Pharma Data

AUGUST 29, 2020

Phase II results are promising for treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disorder; 1,2 second Phase II study with LNP023 monotherapy in anti-C5 naïve PNH patients ongoing . All patients required RBC transfusions prior to starting LNP023 treatment. “In Peffault de Latour.

Treatment 52

Treatment Disease Small Molecule Production 52

The Pharma Data

DECEMBER 15, 2020

CHIPSCREEN BIOSCIENCES BIOSCIENCES will exclusively grant HISUN PHARMACEUTICAL the right to promote Bilessglu® (Chiglitazar Sodium tablets), independently developed and manufactured by its wholly-owned subsidiary CHENGDU CHIPCREEN PHARMACEUTICAL CO., CHIPCREEN BIOSCIENCES remains as the owner and manufacturer of the drug.

Pharmaceuticals 40

Pharmaceuticals Small Molecule Clinical Trials Production 40

Agency IQ

APRIL 19, 2024

As the FDA’s Center for Drug Evaluation and Research (CDER) characterized it in a 2023 call for comments : “Evolving understanding of disease biology and molecular pharmacology, advancements in drug discovery, and growth in novel therapeutic platforms (i.e., In particular, regulations in both the U.S.

Clinical Trials 40

Clinical Trials Trials Science FDA 40

Drug Discovery World

OCTOBER 4, 2023

University of Queensland (UQ) researchers have identified a novel drug target with the potential to overcome drug resistance and prevent tumour regrowth in cancer patients. The newly identified molecule is not currently a target for treatment, opening the potential for drug development.

Small Molecule 130

Small Molecule Drug Development International Research 130

Drug Discovery World

MAY 11, 2023

The drug has already shown particular promise in ovarian cancer in a first-in-human, Phase I trial led by researchers at the ICR and The Royal Marsden NHS Foundation Trust. Algok Bio’s exclusive license agreement with BTG grants the former the rights to develop and commercialise idetrexed worldwide.

Trials 130

Trials Small Molecule Drugs Pharmaceutical Companies 130

Drug Discovery World

JANUARY 12, 2023

Oksana Sirenko looks at the advantages and limitations of using organoids from human cell sources in drug development and drug screening. . Altering one base pair can drastically change how the gene’s protein product functions, while mutations can lead to the development of a range of genetic disorders. .

Drugs 246

Drugs Disease Drug Development Therapies 246

The Pharma Data

OCTOBER 26, 2020

V590 — a SARS-CoV-2 vaccine candidate in development in collaboration with the International AIDS Vaccine Initiative (IAVI) that uses a recombinant vesicular stomatitis virus (rVSV) platform, the same platform used for Merck’s approved Ebola Zaire virus vaccine, will enter Phase 1 development shortly.

Vaccine 40

Vaccine Trials Licensing Licensing 40

Drug Target Review

JULY 7, 2023

In pregnant individuals, maternal autoantibodies can even attack the organs and tissues of the foetus, 1-9 Many of these diseases are rare, with no safe, targeted, advanced and effective treatment options approved for patients in need. By stopping or blocking the normal work of these molecules, diseases can often be slowed or even stopped.

Disease 98

Disease Immune Response Therapies Treatment 98

The Pharma Data

SEPTEMBER 8, 2020

About AstraZeneca AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

SEPTEMBER 8, 2020

(LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Cambridge, UK.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Premier Consulting Blog

MAY 31, 2023

As a cornerstone of the drug development process, nonclinical investigational new drug (IND)-enabling studies are essential for supporting first-in-human (FIH) dosing for novel therapeutics. Pharmacology A typical IND-enabling package includes information on the primary, secondary, and safety pharmacology of the drug.

Packaging 52

Packaging Pharmacokinetics Small Molecule FDA 52

Vial

FEBRUARY 19, 2024

I always had the concept of morbidity of medicine and trying to find treatments for patients that are safe and effective and doesn’t have a lot of side effects. We embarked on the development of the next-generation BTK inhibitor, which now is approved called, Calquence. I started my career as a urologist, nevertheless.

Small Molecule 52

Small Molecule Therapies Treatment Science 52

New Drug Approvals

SEPTEMBER 13, 2024

4] [6] Aticaprant was originally developed by Eli Lilly , was under development by Cerecor for a time, and is now under development by Janssen Pharmaceuticals. [2] 12] Positron emission tomography imaging revealed that brain KORs were almost completely saturated by the drug 2.5 2] Aticaprant is taken by mouth. [1]

Treatment 62

Treatment Pharmacokinetics Clinical Trials Pharmaceuticals 62

Drug Target Review

SEPTEMBER 26, 2024

Cresset delivers software solutions and contract research expertise enabling companies around the world to accelerate their small molecule discovery processes efficiently and effectively. This enables us to explore novel drug candidates that could be more effective or have fewer side effects than existing treatments and drugs.

Drugs 64

Drugs Production Small Molecule Research 64

The Pharma Data

OCTOBER 18, 2020

Despite recent advances in the targeted treatment of AML, the majority of patients will relapse or remain refractory to current therapies and there remains a significant unmet need for new therapies. About CG-806. Forward Looking Statements. This press release contains forward-looking statements within the meaning of Canadian and U.S.

Small Molecule 40

Small Molecule Clinical Trials Trials Therapies 40

Agency IQ

APRIL 19, 2024

Treatment for MM may be lifelong, with patient and disease characteristics guiding the course of treatment. Patients frequently receive up to four therapies at once and go through multiple prolonged courses of treatment to keep recurrence and progression at bay.

FDA 40

FDA Disease Trials Clinical Trials 40

Drug Target Review

FEBRUARY 15, 2024

Protection from a vaccine may not be durable or complete, and persons may still require treatment with medications for their infection. 11 Health agencies globally must collaborate with academic research centres and industry to address this important gap in drug treatments for pandemic-prone pathogens. Antiviral Research.

Drug Development 122

Drug Development Virus Vaccine Government 122

Agency IQ

DECEMBER 11, 2023

The areas within oncology that have seen the most success in terms of new and effective treatment options are now entering a new paradigm where the terms “success” and “harm” are being redefined. As more data have been collected on products previously approved, regulators have started to look back at them with a more critical gaze.

FDA 40

FDA Science Clinical Trials Trials 40

Drug Discovery World

MAY 10, 2023

While the discovery phase – which includes target discovery, target validation, lead compound identification, and lead compound optimisation – averages several years and $200 million, the majority of the research, time, and financial spend takes place downstream in drug development.

Small Molecule 130

Small Molecule Pharmaceutical Companies Animal Testing Pharmaceuticals 130

The Premier Consulting Blog

APRIL 25, 2023

Opinions regarding how the new act will impact the industry vary, with predictions ranging from everything remaining at the status quo to the end of animal testing for new drug development and approvals. In the US, new small molecule drugs are developed under the requirements of Sections 505(b)(1) and 505(b)(2) of the FFDCA.

FDA 52

FDA Animal Testing Pharmacokinetics Small Molecule 52

The Pharma Data

DECEMBER 27, 2020

The NRDL’s inclusion of tislelizumab, BRUKINSA, and XGEVA will help expand access to these high-quality oncology treatments across China and alleviate the financial burden for many cancer patients and their families. “We

Production 52

Production Therapies Treatment Drugs 52